House Subcommittee Approves $2.1 Billion for FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

House Subcommittee Approves $2.1 Billion for FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (June 26)—The US Food and Drug Administration will have a $2.1 billion budget next year if the fiscal year 2009 bill markup by the US House of Representatives’ Agriculture Appropriations Subcommittee passes through Congress. The subcommittee approved for FDA $282 million above the President’s budget request for FY 2009.

In her opening statement at last week’s meeting, Subcommittee Chairwoman Rosa DeLauro (D-CT) noted that the administration had recently made a request for an additional $275 million for FDA [see full story]. “To be sure, this is a long overdue acknowledgment that the status quo is not working when it comes to our broken food safety system,” she said. “So we are indeed, eager to fully fund that request and provide the critical resources necessary for reform.”

DeLauro added her concern that the administration has yet to indicate how FDA should use these additional funds. “…Real reform requires real management – so this committee will convene hearings and require spending reports to ensure the money is used as effectively as possible,” she said.

The marked-up Subcommittee bill goes to the House Appropriations Committee next where it will be further reviewed and marked up before going to the full House of Representatives.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here